Unknown PHASE4 INTERVENTIONAL 2-arm NCT02634541

Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis (PETSPA)

The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis

Sponsor: AbbVie

Conditions Ankylosing Spondyloarthritis

Interventions Adalimumab PET/CT imaging

Updated 8 times since 2017 Last updated: Feb 22, 2017 Started: Jan 31, 2016 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Ankylosing Spondyloarthritis, this trial is ongoing. The trial is conducted by AbbVie and has accumulated 8 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Apr 2020 — Jan 2021 [monthly]

Unknown Status PHASE4
Mar 2019 — Apr 2020 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE4
Mar 2017 — Jun 2018 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Jan 2017 — Mar 2017 [monthly]

Not Yet Recruiting PHASE4

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
University of Helsinki

Data source: University of Helsinki

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Helsinki, Finland
• Lahti, Finland